Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]SL2511.88
- Development stage
- Preclinical
- Lead developer
- Center for Addiction and Mental Health
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[11C]SL2511.88 (also known as [11C]SL25.1188) is a carbon-11 labeled, reversibly binding positron emission tomography (PET) radioligand that selectively targets monoamine oxidase B (MAO-B). Originally developed as a selective MAO-B inhibitor by Sanofi-Synthélabo, the compound was subsequently translated into a PET radiotracer for clinical neuroimaging. Because MAO-B is highly expressed in astrocytes and upregulated during neuroinflammation, [11C]SL2511.88 serves as an in vivo biomarker for astrogliosis. It is widely used in clinical research to investigate neuroinflammatory and neurodegenerative processes across various conditions, including major depressive disorder (MDD), bipolar depression, traumatic brain injury (TBI), posttraumatic stress disorder (PTSD), Alzheimer's disease (AD), and alcohol use disorder (AUD).
- Other names
- (5S)-5-(methoxymethyl)-3-[6-(4,4,4-trifluorobutoxy)-1,2-benzisoxazol-3-yl]-2-oxazolidinone-2-11C(S)-5-methoxymethyl-3-[6-(4,4,4-trifluorobutoxy)benzo[d]isoxazol-3-yl]oxazolidin-2-[11C]-onecarbon-11 labeled SL25.1188carbon11 labeled SL25.1188carbon 11 labeled SL25.1188
02
Targets
MAOB (Monoamine oxidase B)
Beyond the preview
Go deeper on [11C]SL2511.88.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [11C]SL2511.88.